Postmenopause

What it is

Postmenopause is the life stage beginning 12 months after the final menstrual period and continuing for the rest of a woman's life, defined by persistently low estrogen and progesterone due to permanent cessation of ovarian function. Also called the postmenopausal stage or post-menopause, it is distinct from menopause itself — which is the single point in time confirmed by 12 consecutive months without a period — and from perimenopause, the hormonal transition leading up to it. In Canada, where average life expectancy for women exceeds 84 years and the median age of natural menopause is approximately 51, most women spend roughly one-third of their lives in postmenopause. Understanding the health implications of this stage is one of the highest-yield areas of preventive medicine for Canadian women.

Unlike perimenopause, postmenopause is not a transition — it is a sustained biological state. Acute vasomotor symptoms such as hot flashes and night sweats often ease over time, but for 25–50% of women they persist beyond five years, and for roughly 10% they continue for more than a decade. The longer-term consequences of sustained hormone deficiency — on bone density, cardiovascular health, genitourinary tissues, and cognitive function — become the dominant clinical concerns.

Causes and mechanism

Postmenopause is the natural result of complete ovarian follicle depletion. Once follicles are exhausted, the ovaries can no longer produce meaningful amounts of estradiol or progesterone. Key hormonal shifts include:

Hormone	Change in postmenopause	Clinical consequence
Estradiol (E2)	Falls to very low levels	Vasomotor symptoms, bone loss, GSM, cardiovascular risk
Estrone (E1)	Becomes dominant estrogen	Produced by peripheral conversion of adrenal androgens in fat tissue
Progesterone	Virtually absent	No ovulation, no corpus luteum formation
Testosterone	Declines (ovarian production ceases)	Reduced libido, fatigue, muscle changes
FSH / LH	Persistently elevated	Pituitary continues signalling unresponsive ovaries

Postmenopause can also occur earlier than expected through surgical menopause (bilateral oophorectomy), chemotherapy or pelvic radiation, or premature ovarian insufficiency (POI), which affects roughly 1% of women under 40.

Symptoms and diagnosis

Postmenopause presents differently across individuals. Some women have few ongoing symptoms; others manage significant long-term effects.

Continuing or new symptoms:

• Vasomotor symptoms (hot flashes, night sweats) persist in 25–50% of women beyond five years post-menopause
• Genitourinary syndrome of menopause (GSM) — vaginal dryness, painful intercourse, urinary urgency, recurrent UTIs — affects up to 50% of postmenopausal women and worsens progressively without treatment
• Reduced libido and sexual sensitivity
• Sleep disruption, which may improve once night sweats lessen but can persist independently
• Joint aches and changes in muscle mass

Long-term health implications:

• Osteoporosis: Bone loss accelerates in the first 5–10 years after menopause, raising fracture risk at the hip, spine, and wrist. Osteoporosis Canada recommends a DEXA bone density scan at or within two years of menopause for all women.
• Cardiovascular disease: Loss of estrogen's vascular-protective effects drives rising LDL cholesterol, arterial stiffening, and higher rates of hypertension. Cardiovascular disease is the leading cause of death in postmenopausal women — surpassing breast cancer.
• Cognitive changes: Some evidence links postmenopausal estrogen deficiency to increased dementia risk, though the relationship is complex and not fully established.

Diagnosis and monitoring: Postmenopause is a clinical diagnosis confirmed by 12 months of amenorrhea. FSH and estradiol levels may be checked when confirmation is needed — for example, in women using hormonal contraception who cannot track cycle cessation. Recommended monitoring includes DEXA scan, lipid panel, blood pressure, fasting glucose, and age-appropriate mammography and cervical screening per Canadian guidelines.

Treatment options

Management in postmenopause targets symptom relief, bone protection, cardiovascular risk reduction, and quality of life.

Hormone therapy (HT): Continuous combined HT — estrogen plus progestogen taken daily without a break — is the standard regimen in postmenopause, since cyclic bleeding is no longer needed or expected. It effectively relieves persistent vasomotor symptoms and GSM, protects bone density, and may carry cardiovascular benefit when initiated within 10 years of menopause or before age 60 (the "timing hypothesis" or "window of opportunity"). HT can be continued as long as individual benefits outweigh risks, reassessed periodically with a clinician. Women without a uterus may use estrogen alone.

Genitourinary symptoms: Local vaginal estrogen or prasterone (vaginal DHEA, available in Canada as Intrarosa) are highly effective for GSM and considered safe for long-term use, including in women not using systemic HT.

Bone protection: Where fracture risk is elevated, bisphosphonates (e.g., alendronate, risedronate), denosumab, or other anti-resorptive or anabolic agents are used alongside calcium, vitamin D, and weight-bearing exercise.

Cardiovascular risk: Lifestyle modification, statin therapy where indicated, and blood pressure management remain the cornerstones of postmenopausal cardiovascular care.

Non-hormonal vasomotor treatment: Fezolinetant (a neurokinin B receptor antagonist, approved by Health Canada in 2023), SSRIs, SNRIs, and gabapentin are options for women who cannot or prefer not to use HT.

Canadian patients can access postmenopausal care through their family physician, a menopause specialist, or virtual platforms such as Maple, Felix, Cleo, Phoenix, or others — allowing comparison of approaches and prescribing practices.

When to see a clinician in Canada

See a clinician if you experience:

• Hot flashes or night sweats disrupting sleep or daily function
• Vaginal dryness, painful intercourse, or urinary symptoms
• Any postmenopausal vaginal bleeding, however light — this always warrants investigation to exclude endometrial pathology
• A fracture from minimal trauma

Seek proactive review for:

• DEXA bone density scanning if not recently completed
• Cardiovascular risk assessment (lipid panel, blood pressure, glucose)
• Discussion of HT if not yet considered, particularly within the first 10 years of menopause when the benefit-risk profile is most favourable

The Society of Obstetricians and Gynaecologists of Canada (SOGC) supports individualized, ongoing postmenopausal care rather than a single decision point.

Limitations and open questions

Research is still emerging on several aspects of postmenopausal health. The relationship between estrogen deficiency and dementia risk remains incompletely understood — observational data suggest a link, but randomized trial evidence is mixed, and Health Canada has not approved HT for dementia prevention. The optimal duration of HT use has not been established by long-term randomized trials; current guidance is based on expert consensus and observational data. The cardiovascular timing hypothesis — that HT is protective when started early but potentially harmful when started late — is biologically plausible and supported by secondary analyses, but has not been confirmed in a dedicated randomized trial. Evidence on the long-term safety of compounded bioidentical hormone preparations remains limited, and Health Canada has not approved custom-compounded formulations for postmenopausal indications. Individual variation in symptom duration, fracture risk, and cardiovascular trajectory means population-level statistics do not reliably predict outcomes for any one patient.